Agonist News and Research

RSS

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

19 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety.

17 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.

13 Jun 2013

New collaboration to advance cancer immunotherapy research

The Cancer Research Institute, the Ludwig Institute for Cancer Research and Immune Design, a biotech company focused on immune-based therapies for cancer and other human diseases, today announced that they have signed a collaboration agreement to advance cancer immunotherapy research.

13 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in preclinical models in contrast to existing GABAA receptor non-selective agonists, such as benzodiazepines.

10 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

BUSM researchers uncover important clues that may expand treatment options for schizophrenia

Researchers at Boston University School of Medicine have uncovered important clues about a biochemical pathway in the brain that may one day expand treatment options for schizophrenia.

6 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. The project is called the GRADE: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

4 Jun 2013

New animal model provides insight into early stages of Parkinson's disease

At the present, no cure exists for Parkinson's disease, although symptomatic intervention, including treatment with dopamine agonists, can alleviate patients' motor impairment. Parkinson's is the second most common neurodegenerative disorder, after Alzheimer's disease; it is estimated that 100,000 to 300,000 patients are affected by Parkinson's disease in Germany alone.

28 May 2013

TSRI scientists devise new technique to find therapeutic antibodies

Scientists at The Scripps Research Institute have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world's best-selling medicines, diagnostics and laboratory reagents.

24 May 2013

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.

22 May 2013

Study: Use of bronchodilators linked with increased risks of cardiovascular events

A study of older patients with chronic obstructive pulmonary disease (COPD) suggests that new use of the long-acting bronchodilators β-agonists and anticholinergics was associated with similar increased risks of cardiovascular events, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication.

21 May 2013

Exercise-induced bronchoconstriction (EIB) guidelines: an interview with Dr Jonathan Parsons, The Ohio State University Asthma Center

Exercise-induced bronchospasm (EIB) is defined as acute, transient airway narrowing that occurs in association with exercise. Exercise-induced bronchospasm can occur during or, more frequently, after exercise.

21 May 2013

Agonist News and Research

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Transition, Lilly amend agreement to address future development of TT-401

Mount Sinai researchers present several new studies at ENDO 2013

Bristol-Myers Squibb, AstraZeneca release statement on ADA's efforts toward incretin-based therapies

Teva to present abstracts on AZILECT at MDS meeting

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

New collaboration to advance cancer immunotherapy research

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

BUSM researchers uncover important clues that may expand treatment options for schizophrenia

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

New animal model provides insight into early stages of Parkinson's disease

TSRI scientists devise new technique to find therapeutic antibodies

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Study: Use of bronchodilators linked with increased risks of cardiovascular events

Exercise-induced bronchoconstriction (EIB) guidelines: an interview with Dr Jonathan Parsons, The Ohio State University Asthma Center

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News